Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Painful Diabetic Peripheral Neuropathy (PDPN)
View Full LandscapeTarget Indication
Painful Diabetic Peripheral Neuropathy (PDPN)
Clinical Trial
NCT01478607Last updated: 2/9/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Qutenza
Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain.
View on EMA